State-of-the-art Surgery for Hepatocellular Carcinoma

Overview

Journal Langenbecks Arch Surg

Specialty General Surgery

Date 2021 Aug 18

PMID 34405284

Citations 12

Authors

Nikolaos Machairas

Diamantis I Tsilimigras

Timothy M Pawlik

Affiliations

Soon will be listed here.

Abstract

Background: Hepatocellular carcinoma (HCC) is the most commonly diagnosed primary liver tumor with an increasing incidence worldwide. Management of patients with HCC is largely dictated by the presence of cirrhosis, disease stage, underlying liver function, and patient performance status.

Purpose: We provide an update on key aspects of surgical treatment options for patients with HCC. RESULTS & CONCLUSIONS: Liver resection and transplantation remain cornerstone treatment options for patients with early-stage disease and constitute the only potentially curative options for HCC. Selection of patients for surgical treatment should include a thorough evaluation of tumor characteristics and biology, as well as evidence-based use of various available treatment options to achieve optimal long-term outcomes for patients with HCC.

Citing Articles

Decoding the Prognostic Significance and Therapeutic Implications of Inflammation-Based Scores in Hepatocellular Carcinoma: A Comprehensive Review.

Kotsifa E, Machairas N, Angelis A, Nikiteas N, Dimitroulis D, Sotiropoulos G Cancers (Basel). 2024; 16(14).

PMID: 39061188 PMC: 11274930. DOI: 10.3390/cancers16142549.

Caffeic acid phenethyl ester derivative exerts remarkable anti-hepatocellular carcinoma effect, non-inferior to sorafenib, in vivo analysis.

Gong L, Wang W, Yu F, Deng Z, Luo N, Zhang X Sci Rep. 2024; 14(1):14546.

PMID: 38914695 PMC: 11196574. DOI: 10.1038/s41598-024-65496-1.

Which factors predict tumor recurrence and survival after curative hepatectomy in hepatocellular carcinoma? Results from a European institution.

Vaghiri S, Prassas D, Mustafov O, Kalmuk S, Knoefel W, Lehwald-Tywuschik N BMC Surg. 2024; 24(1):101.

PMID: 38589847 PMC: 11003056. DOI: 10.1186/s12893-024-02399-y.

Unveiling the Yin-Yang Balance of M1 and M2 Macrophages in Hepatocellular Carcinoma: Role of Exosomes in Tumor Microenvironment and Immune Modulation.

Papadakos S, Machairas N, Stergiou I, Arvanitakis K, Germanidis G, Frampton A Cells. 2023; 12(16).

PMID: 37626849 PMC: 10453902. DOI: 10.3390/cells12162036.

Unraveling the Significance of EPH/Ephrin Signaling in Liver Cancer: Insights into Tumor Progression and Therapeutic Implications.

Papadakos S, Stergiou I, Gkolemi N, Arvanitakis K, Theocharis S Cancers (Basel). 2023; 15(13).

PMID: 37444544 PMC: 10340246. DOI: 10.3390/cancers15133434.

References

Tsilimigras D, Bagante F, Sahara K, Moris D, Hyer J, Wu L . Prognosis After Resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B Hepatocellular Carcinoma: A Comprehensive Assessment of the Current BCLC Classification. Ann Surg Oncol. 2019; 26(11):3693-3700. DOI: 10.1245/s10434-019-07580-9. View

Benson A, DAngelica M, Abbott D, Abrams T, Alberts S, Anaya D . Guidelines Insights: Hepatobiliary Cancers, Version 2.2019. J Natl Compr Canc Netw. 2019; 17(4):302-310. DOI: 10.6004/jnccn.2019.0019. View

Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H . Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985; 56(4):918-28. DOI: 10.1002/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e. View

Kudo M, Chung H, Osaki Y . Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol. 2003; 38(3):207-15. DOI: 10.1007/s005350300038. View

Chok K, Ng K, Poon R, Lo C, Fan S . Impact of postoperative complications on long-term outcome of curative resection for hepatocellular carcinoma. Br J Surg. 2008; 96(1):81-7. DOI: 10.1002/bjs.6358. View

Taketomi A, Kitagawa D, Itoh S, Harimoto N, Yamashita Y, Gion T . Trends in morbidity and mortality after hepatic resection for hepatocellular carcinoma: an institute's experience with 625 patients. J Am Coll Surg. 2007; 204(4):580-7. DOI: 10.1016/j.jamcollsurg.2007.01.035. View

Wei A, Tung-Ping Poon R, Fan S, Wong J . Risk factors for perioperative morbidity and mortality after extended hepatectomy for hepatocellular carcinoma. Br J Surg. 2003; 90(1):33-41. DOI: 10.1002/bjs.4018. View

Ribero D, Curley S, Imamura H, Madoff D, Nagorney D, Ng K . Selection for resection of hepatocellular carcinoma and surgical strategy: indications for resection, evaluation of liver function, portal vein embolization, and resection. Ann Surg Oncol. 2008; 15(4):986-92. DOI: 10.1245/s10434-007-9731-y. View

Roayaie S, Jibara G, Tabrizian P, Park J, Yang J, Yan L . The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology. 2015; 62(2):440-51. DOI: 10.1002/hep.27745. View

10.

Zhou X, Tang Z, Yang B, Lin Z, Ma Z, Ye S . Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer. 2001; 91(8):1479-86. DOI: 10.1002/1097-0142(20010415)91:8<1479::aid-cncr1155>3.0.co;2-0. View

11.

Yang B, Zheng B, Yang M, Zeng Z, Yang F, Pu J . Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. Hepatol Int. 2018; 12(5):417-428. DOI: 10.1007/s12072-018-9888-4. View

12.

Wang H, Qian Y, Wu M, Cong W . Liver Resection Is Justified in Patients with BCLC Intermediate Stage Hepatocellular Carcinoma without Microvascular Invasion. J Gastrointest Surg. 2019; 24(12):2737-2747. DOI: 10.1007/s11605-019-04251-8. View

13.

Chen S, Jin H, Dai Z, Wei M, Xiao H, Su T . Liver resection versus transarterial chemoembolization for the treatment of intermediate-stage hepatocellular carcinoma. Cancer Med. 2019; 8(4):1530-1539. PMC: 6488138. DOI: 10.1002/cam4.2038. View

14.

Yin L, Li H, Li A, Lau W, Pan Z, Lai E . Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT. J Hepatol. 2014; 61(1):82-8. DOI: 10.1016/j.jhep.2014.03.012. View

15.

Hyun M, Lee Y, Kim J, Lee C, Jung Y, Seo Y . Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: A meta-analysis of high-quality studies. Hepatology. 2018; 68(3):977-993. DOI: 10.1002/hep.29883. View

16.

Labgaa I, Demartines N, Melloul E . Surgical Resection Versus Transarterial Chemoembolization for Intermediate Stage Hepatocellular Carcinoma (BCLC-B): An Unsolved Question. Hepatology. 2018; 69(2):923. DOI: 10.1002/hep.30338. View

17.

Takemura N, Aoki T, Hasegawa K, Kaneko J, Arita J, Akamatsu N . Hepatectomy for hepatocellular carcinoma after perioperative management of portal hypertension. Br J Surg. 2019; 106(8):1066-1074. DOI: 10.1002/bjs.11153. View

18.

Poon R, Fan S, Lo C, Liu C, Ming Lam C, Yuen W . Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: is it justified?. Ann Surg. 2002; 236(5):602-11. PMC: 1422618. DOI: 10.1097/00000658-200211000-00010. View

19.

Nagasue N, Yukaya H, Ogawa Y, Kohno H, Nakamura T . Human liver regeneration after major hepatic resection. A study of normal liver and livers with chronic hepatitis and cirrhosis. Ann Surg. 1987; 206(1):30-9. PMC: 1492934. DOI: 10.1097/00000658-198707000-00005. View

20.

Mehta N, Bhangui P, Yao F, Mazzaferro V, Toso C, Akamatsu N . Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation. 2020; 104(6):1136-1142. DOI: 10.1097/TP.0000000000003174. View